MENLO PARK, Calif. & EDINBURGH, Scotland--(BUSINESS WIRE)--Aug. 7, 2006--Geron Corporation (Nasdaq:GERN - News) and the University of Edinburgh announced today that they have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells (hESCs).
